Pathogenetic and Prognostic Importance of Cyclin D1, Estrogen Receptor, and TAG72 in Cutaneous Vascular Tumors and Pericytic Tumors

Objective: The present study aims to investigate the presence of pericyte loss in malignant vascular tumors and investigate the expression of cell cycle regulators, cyclin D1 and estrogen receptor (ER), and tumor-associated glycoprotein 72 (TAG72) in tumor cells and tumor microenvironment in benign/malignant vascular tumors and benign/malignant pericytic tumors. Methods: Cyclin D1, ER, and TAG72 were examined by immunohistochemistry in 38 cases of tumors of vascular and pericytic origins. The data on metastasis and prognosis of malignant cases were retrieved from the hospital information system. Results: The 38 patients included the following types of neoplasms: hemangioma (n=16), glomus tumor (n=9), epithelioid angiosarcoma (n=8), epithelioid hemangioendothelioma (n=3), infantile hemangiopericytoma (n=1), and malignant glomus tumor (n=1). No statistically significant difference was found in cyclin D1 expression between pericyte-derived tumors and malignant vascular tumors (p=0.508). When benign-malignant vascular and pericytic tumors were compared, no statistically significant difference was found in cyclin D1 expression between the 4 groups (p=0.465). No statistically significant difference was observed in staining between tumors of vascular and pericytic origin (p=0.104). ER expression was detected in only one case of malignant glomus tumor. TAG72 expression was not observed in any of the cases. Conclusion: The present study supports the notion that cyclin D1 may be present as a driver mutation in this group of tumors. The findings of this study did not produce any data to support the hypothesis claiming that pericyte loss led to malignancy. We believe that our results on the comparison of cell cycle protein expressions in cutaneous vascular and pericytic tumors shed light for future studies to elucidate the pathogenesis of this group of rare tumors

Doğuştan pes ekinovarus deformitesinde yumuşak doku ameliyetleri

TEZ2531Tez (Uzamanlık) -- Çukurova Üniversitesi, Adana, 1990.Kaynakça (s. 50-52) var.i, 52(6) s. ; res. ; 30 cm.

Multifocal Epitheloid Hemangiondothelioma: A Case Report

Epiteloid hemanjioendotelyoma malign biyolojik davranış sergileyen nadir bir vasküler tümördür. Sıklıkla yumuşak vasküler endotelyal hücrelerden köken alır fakat karaciğer, akciğer, kemik ve deri gibi pek çok lokalizasyonda bulunabilir. Yavaş büyüyen düşük veya borderline malign tümör olarak kabul edilirler ancak agresif formları da bildirilmiştir. Bu yazıda 24 yaşında yumuşak dokuda multifokal yerleşimli epiteloid hemanjioendotelyoma olgusu klınik, radyolojik ve histopatolojik bulguları ile birlikte sunulmuşturEpitheloid hemangioendothelioma (EHE) is a rare vascular tumor with malignant biological behavior. It arises from vascular endothelial cells, usually within soft tissues, and can occur in almost all locations, but tumor can be found in liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression, but aggressive forms have been described. We present a 24 year-old female case of multifocal epitheloid hemangioendothelioma of the soft tissue with its clinical, radiological and histopathological finding

Yumuşak dokunun nadir görülen tümörlerinde ve odontojenik tümörlerde immünohistokimyasal yöntem ve floresan in situ hibridizasyonla epidermal growth faktör reseptör varlığının gösterilmesi

Amaç: Bu çalışmada amaç, çeşitli odontojenik tümörler ve nadir görülen yumuşak doku tümörlerinde epidermal growth faktör reseptörün (EGFR) rolünü ortaya koyabilmektir. Gereç ve Yöntem: Bu çalışmada 2002-2010 yılları arasında Çukurova Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı'nda tanı almış onbir odontojenik tümör olgusu ve onyedi nadir görülen yumuşak doku tümörü olgusu olmak üzere toplam 28 olgu incelenmiştir. Bu olgularda immünohistokimyasal olarak EGFR boyanması ve FISH yöntemi ile genetik anormallik araştırılmıştır. Bulgular: immünohistokimyasal olarak uygulanan EGFR ile onbir olgu pozitif boyanmıştır. FISH yöntemi ile ise sekiz olguda genetik anormallik saptanmıştır. Odontojenik tümör olgularımızın dokuzunda (%81,8) immünohistokimyasal yöntemle overekspresyonunun saptanmıştır. Sonuç: Yumuşak doku tümörlerinde ise kordoma patogenezinde EGFR'nin önemi bulgularımızla tekrar vurgulanmış olup, daha önce EGFR varlığı gösterilmemiş olan odontojenik tümörler ile retiform ve kompozit hemanjioendotelyoma grubu tümörlerde de EGFR'nin rolü olduğu ileri sürülebilir. EGFR tanısal amaçlı kullanılabileceği gibi, anti-EGFR ilaçların hedefini teşkil ettiğinden, hastaların tedavi yönetiminde de oldukça değerlidir.Purpose: The aim of this study is to investigate the role of epidermal growth factor receptor (EGFR) in odontogenic tumors and rare soft tissue tumors. Material and Methods: This study includes 28 cases (11 cases of odontogenic tumors and 17 cases of soft tissue tumors) which were diagnosed at Cukurova University Medical Faculty, Department of Pathology between 2002 and 2010. They were evaluated for immunohistochemical staining of EGFR and the presence of genetic abnormality by FISH method. Results: Eleven cases were positively stained by immunohistochemistry. Eight cases had genetic abnormality of EGFR gene by FISH method. Nine of eleven overexpression of EGFR by immunohistochemical method or FISH method. Conclusion: Our findings highlight that EGFR plays an important role in chordoma pathogenesis in soft tissue tumors. In addition to odontogenic tumors; two cases of vascular hemangioendothelioma, amplification. Interestingly, there is no avaliable data about EGFR gene status in these tumors. EGFR can be used for diagnostic purposes. Also, it is a target for anti-EGFR therapy. Therefore, EGFR gene status is a valuable marker for therapeutic management

Elastofibroma dorsi: Clinical evaluation of 61 cases and review of theliterature

Objective: ElastoŞbroma dorsi (ED) is a rare, benign, soft tissue tumor typically located between inferiorcorner of scapula and posterior chest wall causing mass, scapular snapping, and pain. When classicsymptoms and localization are present, it is diagnosed without biopsy and treated with marginalresection. This study retrospectively analyzed patients operated on for ED to evaluate presentingsymptoms, tumor size, complications, and clinical results, and to suggest optimal treatments.Methods: This study included 51 patients who underwent surgery for ED in 2 different clinics between2005 and 2015. Patient age, gender, profession, side affected, symptoms, average duration of symptoms,and tumor size were researched. Radiological examinations of patients were evaluated. Patients withlesions larger than 5 cm in size were operated on. Postoperative complications, recurrence, and functional results were evaluated using Constant score and compared to preoperative values.Results: A total of 61 operated lesions of 51 patients clinically and radiologically diagnosed with ED wereretrospectively evaluated. Average length of time patient experienced symptoms was 11.21 months.Lesions in 19 (37.2%) patients were bilateral, 10 of which were symptomatic and larger than 5 cm in size,meeting indication for surgery. Average lesion diameter was 8.7 cm. Average follow-up was 26.89months. Average of preoperative Constant score of 67.28 subsequently increased to 92.88 (<0.05).Seroma and hematoma were observed in 11.5% of patients.Conclusion: Generally, good clinical results can be obtained with marginal resection without requiring abiopsy, considering classic complaints and radiological appearance of ED.Level of evidence: Level IV, Therapeutic study.&copy; 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This isan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Objective: ElastoŞbroma dorsi (ED) is a rare, benign, soft tissue tumor typically located between inferiorcorner of scapula and posterior chest wall causing mass, scapular snapping, and pain. When classicsymptoms and localization are present, it is diagnosed without biopsy and treated with marginalresection. This study retrospectively analyzed patients operated on for ED to evaluate presentingsymptoms, tumor size, complications, and clinical results, and to suggest optimal treatments.Methods: This study included 51 patients who underwent surgery for ED in 2 different clinics between2005 and 2015. Patient age, gender, profession, side affected, symptoms, average duration of symptoms,and tumor size were researched. Radiological examinations of patients were evaluated. Patients withlesions larger than 5 cm in size were operated on. Postoperative complications, recurrence, and functional results were evaluated using Constant score and compared to preoperative values.Results: A total of 61 operated lesions of 51 patients clinically and radiologically diagnosed with ED wereretrospectively evaluated. Average length of time patient experienced symptoms was 11.21 months.Lesions in 19 (37.2%) patients were bilateral, 10 of which were symptomatic and larger than 5 cm in size,meeting indication for surgery. Average lesion diameter was 8.7 cm. Average follow-up was 26.89months. Average of preoperative Constant score of 67.28 subsequently increased to 92.88 (<0.05).Seroma and hematoma were observed in 11.5% of patients.Conclusion: Generally, good clinical results can be obtained with marginal resection without requiring abiopsy, considering classic complaints and radiological appearance of ED.Level of evidence: Level IV, Therapeutic study.&copy; 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This isan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/

Incidence and clinical characteristics of acute rheumatic fever in Turkey: Results of a nationwide multicentre study

© 2021 Paediatrics and Child Health Division (The Royal Australasian College of Physicians)Aim: To evaluate the incidence and clinical features of acute rheumatic fever (ARF) in Turkey, following the revised Jones criteria in 2015. Methods: This multicentre study was designed by the Acquired Heart Diseases Working Group of the Turkish Pediatric Cardiology and Pediatric Cardiac Surgery Association in 2016. The data during the first attack of 1103 ARF patients were collected from the paediatric cardiologists between 1 January 2016 and 31 December 2016. Results: Turkey National Institute of Statistics records of 2016 were used for the determination of ARF incidence with regard to various cities and regions separately. The estimated incidence rate of ARF was 8.84/100 000 in Turkey. The ARF incidence varied considerably among different regions. The highest incidence was found in the Eastern Anatolia Region as 14.4/100 000, and the lowest incidence was found in the Black Sea Region as 3.3/100 000 (P < 0.05). Clinical carditis was the most common finding. The incidence of clinical carditis, subclinical carditis, polyarthritis, aseptic monoarthritis, polyarthralgia and Sydenham's Chorea was 53.5%, 29.1%, 52.8%, 10.3%, 18.6% and 7.9%, respectively. The incidences of clinical carditis, subclinical carditis, polyarthritis and polyarthralgia were found to be significantly different among different regions (P < 0.05). Conclusion: The findings of this nationwide screening of ARF suggest that Turkey should be included in the moderate-risk group